CEO Update - 11 March 2024

Spring Budget 2024 – key life science announcements

The Chancellor's Budget last week had plenty for UK life sciences. The BIA’s mission to unlock pension funds for investment into UK life sciences took a great leap forward with the announcement that the life sciences team of Intermediate Capital Group (ICG) has successfully partnered with Phoenix Group, the UK’s largest pensions provider, with the support of the Government’s Long-term Investment for Technology and Science (LIFTS) initiative.

Many of you joined our engaging webinar on "Life sciences and politics in Spring 2024," where we dissected the latest news with the BIA's Martin Turner. You can now catch up on the key takeaways in this excellent blog post and watch the recording for a deeper dive.

All the Spring Budget documents and the Chancellor’s speech can be found on the Treasury website.

The WHO declared COVID-19 a pandemic four years ago today

As the pandemic recedes into the rearview mirror of recent history it was good to hear Kate Bingham on the BBC Radio 4's Today program this morning give a realistic assessment of where we are now as a country. Kate’s interview starts two hours 38 minutes into the show. This week we've also seen the draft negotiating text for a pandemic agreement published online by KEI, the discussion of this text will continue until the World Health Assembly and I am attending an all-party parliamentary group meeting today where I will be stressing the importance of practical measures to scale up production and distribution are at the front of any future agreement.

New Chair for TenU

Congratulations to Tim Haines who has been appointed the new Chair of TenU. TenU is an international collaboration formed to capture effective practices in research commercialisation and share these with governments and higher education communities. Its members work together to increase the societal impact of research.

BIA in Cambridge, Scotland and Brussels this week

It's a really busy week of meetings and I'm really sorry that commitments to EuropaBio in Brussels keep me from both Scotland’s Life Sciences Annual Awards and Dinner and our excellent Women in Biotech networking event scheduled tomorrow for Cambridge. It's great to see the vibrancy of our sector around the country and I know the networks that are being built will stand all participants in good stead for the future. 

Deep dive into Deep Biotech at IBioIC

Join the BIA’s Linda Bedenik and George Caterer at the IBioIC 10th anniversary conference, the UK's biggest industrial biotech event taking place in Glasgow on 13 and 14 March. Catch us at our stand with our sponsors throughout the conference, we’ll be showcasing our Deep Biotech report at the Industrial Biotechnology Leadership Forum (IBLF) and attending the Scottish life sciences dinner. It's the perfect opportunity to discuss the future of Deep Biotech and how we can work together to unlock its potential.

Read our latest blog on the concept of Deep Biotech and how advancements in biotechnology offer solutions to sustainability challenges like plastic waste and fossil fuel reliance.

Jobs at BIA

Have you looked at the BIA's jobs board recently? Not only are there some great opportunities amongst member companies but we are also hiring. If you fancy a role with a bird's eye view across the sector delivering real impact in a not-for-profit format, we'd love to hear from you.

 

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Jim Faulkner, Nicole Mather and Carolyn Porter join the Cell and Gene Therapy Catapult as Non-Executive Directors

London, United Kingdom, 29 April 2024: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed three new Non-Executive Directors to its board: Jim Faulkner; Nicole Mather; and Carolyn Porter.

Abzena launches EpiScreen® 2.0, a next-generation immunogenicity tool for de-risking the development of complex biologics

Abzena has announced the launch of its enhanced hashtag#bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical hashtag#immunogenicity in protein, antibody, and gene therapy therapeutics.

RNID shine a spotlight on the hearing therapeutics landscape

In this blog, Melissa Hayman, Hearing Therapeutics Manager at RNID, BIA’s charity partner of the year introduces a blog series to be published over the coming months which will examine the hearing therapeutics landscape.

Continuity and change: Labour’s life science strategy

​​​​Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.

CEO Update - 22 April 2024

The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.

Step up and create more inclusive workplaces within the biotech sector

In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. With Deaf Awareness Week 2024 (6-12 May) fast approaching, the BIA has teamed up with its charity partner, RNID, to offer valuable resources and initiatives for creating more inclusive workplaces across the biotech sector.

University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations

University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.

Investing in life science – learnings from the first round of investments from Discovery Park Ventures

Launched in May 2022 by thriving life science community Discovery Park, Discovery Park Ventures (DPV) is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth. Initially a £1 million fund, DPV has now expanded to £3 million.

AI in life sciences: future-proofing strategies

In the final piece of the 'AI in life sciences' series, Jenny Yu, Marsh’s Life Sciences industry practice leader and experts from law firm Kennedys emphasize essential steps for life sciences companies to develop and implement a successful AI business strategy. They delve into effective management of outcomes from AI technologies and strategies to mitigate potential risks.

CEO Update - 15 April 2024

In case you missed it last week, post-Brexit border paperwork and inspections have been postponed for the life sciences sector, thanks to BIA work. Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine

CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

More within